Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer - Interventional, prospective, multisite, proof-of-concept, single-arm trial, using organoids to predict efficacy of adjuvant treatment in resectable pancreatic cancer - the UNITEPANC trial of the AIO Pancreatic Cancer Group

• Gemcitabine mono: 6 cycles of gemcitabine (1000mg/m2, d1, 8 and 15, Q4W) • Gemcitabine/Capecitabine: 6 cycles of gemcitabine (1000mg/m2, d1, 8 and 15, Q4W) plus capecitabine (1660mg/m2, d1-21, Q4W) • Capecitabine: 8 cycles of fluoropyrimidine (capecitabine, 2500 mg/m2, d1-14, Q3W) • Gemcitabine/nab-Paclitaxel: 6 cycles of nab-Paclitaxel/Gemcitabine (nab-Paclitaxel 125 mg/m2, Gemcitabine 1000 mg/m2, d1, 8, 15, Q4W) • mFOLFIRINOX: 12 cycles of mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, 5-FU 2400 mg/m2, Q2W

Status: In Vorbereitung

Klinische Settings

Beteiligte

Identifier

Kontakt